Organic compounds as muscarinic m4 receptor positive allosteric modulators (m4pams)
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SUVEN LIFE SCI LTD
- Filing Date
- 2024-12-21
- Publication Date
- 2026-07-17
AI Technical Summary
Existing pharmacological treatments for mental and neurological disorders such as schizophrenia and Alzheimer's disease have dose-limiting side effects, leading to non-compliance and partial responses. Furthermore, it is difficult to develop muscarinic M4 receptor positive allosteric modulator (PAM) compounds that are selective and safe for M4 receptor subtypes.
A novel class of muscarinic M4 receptor PAM compounds has been developed, which exhibit strong affinity for the M4 receptor, selectivity, acceptable pharmacokinetic properties, and good brain permeability. They positively regulate the M4 receptor by acting on its allosteric binding site.
These compounds demonstrated effective cognitive enhancement and antipsychotic drug-like activity in animal models, with reduced side effects and improved treatment efficacy and safety.
Smart Images
Figure CN122422318A_ABST